HYDROXYCHLOROQUINE SULFATE

Drug Sandoz Inc.
Total Payments
$31,256
Transactions
8
Doctors
2
Companies
2

Payment Trends by Year

Year Amount Transactions Doctors
2023 $930.00 2 2
2022 $2,300 1 0
2020 $28,026 5 0

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $30,326 6 97.0%
Consulting Fee $930.00 2 3.0%

Payments by Type

Research
$30,326
6 transactions
General
$930.00
2 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
PATCH 2&3:PREVENTION & TREATMENT OF COVID-19 (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2) WITH HYDROXYCHLOROQUINE Sandoz Inc. $11,880 0
THE PATCH TRIAL (PREVENTION AND TREATMENT OF COVID-19 WITH HYDROXYCHLOROQUINE) (PATCH) Sandoz Inc. $9,000 0
CDRB436AUS37T Sandoz Inc. $4,536 0
BAMM2 BRAF AUTOHPHAGY MEK INHIBITION IN MELANOMA Sandoz Inc. $2,300 0
HYDROXYCHLOROQUINE FOR COVID-19 POST-EXPOSURE PROPHYLAXIS (PEP) Sandoz Inc. $1,800 0
OUTCOMES RELATED TO COVID-19 TREATED WITH HYDROXYCHLOROQUINE AMONG IN-PATIENTS WITH SYMPTOMATIC DISEASE (ORCHID) Sandoz Inc. $810.00 0

Top Doctors Receiving Payments for HYDROXYCHLOROQUINE SULFATE

Doctor Specialty Location Total Records
Unknown Philadelphia, PA $30,326 6
, MD Rheumatology Marietta, OH $580.00 1
Ross Miller Public Health & General Preventive Medicine Los Angeles, CA $350.00 1

About HYDROXYCHLOROQUINE SULFATE

HYDROXYCHLOROQUINE SULFATE is a drug associated with $31,256 in payments to 2 healthcare providers, recorded across 8 transactions in the CMS Open Payments database. The primary manufacturer is Sandoz Inc..

Payment data is available from 2020 to 2023. In 2023, $930.00 was paid across 2 transactions to 2 doctors.

The most common payment nature for HYDROXYCHLOROQUINE SULFATE is "Unspecified" ($30,326, 97.0% of total).

HYDROXYCHLOROQUINE SULFATE is associated with 6 research studies, including "PATCH 2&3:PREVENTION & TREATMENT OF COVID-19 (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2) WITH HYDROXYCHLOROQUINE" ($11,880).